Kala Pharmaceuticals (NASDAQ:KALA) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Friday, BidAskClub reports.

A number of other equities analysts also recently commented on KALA. Northland Securities restated a “buy” rating and set a $17.00 target price on shares of Kala Pharmaceuticals in a report on Friday, August 7th. Jefferies Financial Group downgraded Kala Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their target price for the company from $21.00 to $10.00 in a report on Monday, September 14th. ValuEngine downgraded Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 1st. Zacks Investment Research downgraded Kala Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 14th. Finally, Wedbush restated a “buy” rating and set a $39.00 target price on shares of Kala Pharmaceuticals in a report on Monday, October 5th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. Kala Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $18.50.

Shares of KALA stock opened at $8.04 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 11.29 and a current ratio of 11.63. Kala Pharmaceuticals has a fifty-two week low of $3.24 and a fifty-two week high of $14.68. The stock has a 50 day moving average price of $8.36 and a two-hundred day moving average price of $10.05. The company has a market capitalization of $450.72 million, a P/E ratio of -3.54 and a beta of 0.32.

Kala Pharmaceuticals (NASDAQ:KALA) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.42) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.42). Kala Pharmaceuticals had a negative return on equity of 105.36% and a negative net margin of 1,993.41%. The firm had revenue of $0.83 million during the quarter, compared to the consensus estimate of $0.76 million. As a group, equities analysts predict that Kala Pharmaceuticals will post -1.77 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the stock. Marshall Wace LLP purchased a new stake in shares of Kala Pharmaceuticals during the first quarter valued at $325,000. State Street Corp lifted its holdings in Kala Pharmaceuticals by 18.1% in the first quarter. State Street Corp now owns 428,414 shares of the company’s stock valued at $3,766,000 after acquiring an additional 65,576 shares during the period. Victory Capital Management Inc. lifted its holdings in Kala Pharmaceuticals by 82.2% in the first quarter. Victory Capital Management Inc. now owns 7,359 shares of the company’s stock valued at $65,000 after acquiring an additional 3,320 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in Kala Pharmaceuticals by 102.0% in the first quarter. BNP Paribas Arbitrage SA now owns 8,313 shares of the company’s stock valued at $73,000 after acquiring an additional 4,198 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its holdings in Kala Pharmaceuticals by 12.6% in the first quarter. Parametric Portfolio Associates LLC now owns 156,985 shares of the company’s stock valued at $1,380,000 after acquiring an additional 17,544 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Featured Story: Commodities

Analyst Recommendations for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.